Photo by hdbernd from unsplash
Immune checkpoint inhibitors (ICIs) improve cancer outcomes but are also associated with immune‐related adverse events (irAEs), which pose significant challenges for clinical management. Click to show full abstract
Immune checkpoint inhibitors (ICIs) improve cancer outcomes but are also associated with immune‐related adverse events (irAEs), which pose significant challenges for clinical management.
Keywords:
toxic effects;
decoding fatal;
checkpoint inhibitor;
effects checkpoint;
fatal toxic;
inhibitor therapy
Journal Title: British journal of pharmacology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British journal of pharmacology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!